IN8bio
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell IN8bio and other ETFs, options, and stocks.About INAB
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S.
CEOWilliam T. Ho
CEOWilliam T. Ho
Employees18
Employees18
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2016
Founded2016
Employees18
Employees18
INAB Key Statistics
Market cap11.96M
Market cap11.96M
Price-Earnings ratio-0.35
Price-Earnings ratio-0.35
Dividend yield—
Dividend yield—
Average volume142.89K
Average volume142.89K
High today$2.72
High today$2.72
Low today$2.21
Low today$2.21
Open price$2.31
Open price$2.31
Volume236.46K
Volume236.46K
52 Week high$12.53
52 Week high$12.53
52 Week low$1.17
52 Week low$1.17
Stock Snapshot
IN8bio(INAB) stock is priced at $2.59, giving the company a market capitalization of 11.96M. It carries a P/E multiple of -0.35.
On 2026-01-16, IN8bio(INAB) stock moved within a range of $2.21 to $2.72. With shares now at $2.59, the stock is trading +17.2% above its intraday low and -4.8% below the session's peak.
Trading activity shows a volume of 236.46K, compared to an average daily volume of 142.89K.
The stock's 52-week range extends from a low of $1.17 to a high of $12.53.
The stock's 52-week range extends from a low of $1.17 to a high of $12.53.
INAB News
TipRanks 4d
IN8bio presents Phase I/II data from INB-200 trialsIN8bio (INAB) reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials in newly diagnosed glioblastoma. The prior results were present...
People also own
Based on the portfolios of people who own INAB. This list is generated using Robinhood data, and it’s not a recommendation.